NIAID describes research priorities to fight drug-resistant tu...(o collaborates with the Centers for Dise...),Health

To prevent the further emergence and spread of MDR and XDR TB, the NIAID agenda identifies areas of biomedical research that are likely to contribute substantially to a global public health response. Building on existing efforts within the international network of TB research, NIAIDs priorities include efforts to

• Develop and test reliable technologies to rapidly diagnose TB and to identify drug resistance
• Define the most effective use of existing TB therapies and other antibiotics available to treat drug-resistant TB and develop new drugs, particularly to treat MDR and XDR TB
• Better understand the basic biology of TB-causing bacteria and their interaction with the human host that underlie the development of drug-resistant TB
• Understand the epidemiology of drug-resistant TB
• Investigate the various manifestations of TB in adults, children and those with co-infections, including HIV/AIDS
• Conduct research to develop new vaccines and other preventive strategies

NIAID is leading and sponsoring research activities to create a foundation of knowledge for the discovery of new diagnostics, drugs and vaccines. The Institute also supports the efforts of organizations, such as drug companies and public-private partnerships, to further develop these products into tools and approaches that enhance the quality of care for people with TB.

Only a concerted global effort can counteract the rise of drug-resistant TB, notes Dr. Fauci. Development of improved diagnostics and better treatment and control strategies will depend on collaboration with our partners at every research step, from basic science to large clinical trials.

'/>"/>